Kent Andrea J, Sketris Ingrid S, Johnston B Lynn, Sommers Ryan B
, BScPharm, PharmD, is with the Pharmacy Department, Colchester East Hants Health Authority, Truro, Nova Scotia.
Can J Hosp Pharm. 2009 Jan;62(1):12-20. doi: 10.4212/cjhp.v62i1.112.
Antimicrobial resistance results in increased morbidity, mortality, and costs to the health care system. Evidence suggests an association between the use of antimicrobials in hospitals and the development of antimicrobial resistance. Fluoroquinolones constitute one group of antimicrobials that are effective against a variety of bacterial infections, yet they may be subject to misuse. Many hospitals in Nova Scotia have implemented policies to improve antimicrobial prescribing, but the impact of these policies on utilization is unknown.
To evaluate the use of fluoroquinolones in Nova Scotia hospitals using the World Health Organization's Anatomical Therapeutic Chemical classification system with defined daily doses (ATC/DDD) and to examine the influence of hospital policies for utilization of fluoroquinolones in community-acquired pneumonia.
During the study period (April 1, 1997, to March 31, 2003), fluoroquinolones were administered at 31 of the 37 hospitals in Nova Scotia's 9 district health authorities. Hospital administrative data, hospital characteristics, and pharmaceutical purchasing data related to use of these drugs were aggregated using the ATC/DDD methodology for the fiscal years 1997/1998 to 2002/2003. District pharmacy directors were surveyed to obtain information about district and individual hospital antibiotic policies. Descriptive statistics were calculated, and univariable regression and multilevel analyses were performed.
Mean overall fluoroquinolone use increased over the study period, from 47.2 DDD/1000 bed-days per year in fiscal year 1997/1998 to 163.8 DDD/1000 bed-days per year in fiscal year 2002/2003 (p < 0.001). Multilevel analysis showed that utilization policies aimed at appropriate prescribing did not affect the use of fluoroquinolones.
This study revealed that drug purchasing, hospital administrative, and diagnostic data could be combined to compare the utilization of fluoroquinolones among different hospitals and district health authorities. Utilization policies had little effect on the amount, type, or route of fluoroquinolone use.
抗菌药物耐药性导致发病率、死亡率上升,以及医疗保健系统成本增加。有证据表明,医院中抗菌药物的使用与抗菌药物耐药性的产生之间存在关联。氟喹诺酮类药物是一类对多种细菌感染有效的抗菌药物,但它们可能被滥用。新斯科舍省的许多医院已实施政策以改善抗菌药物的处方开具情况,但这些政策对药物使用的影响尚不清楚。
使用世界卫生组织的解剖学治疗学化学分类系统及限定日剂量(ATC/DDD)评估新斯科舍省医院氟喹诺酮类药物的使用情况,并研究医院政策对社区获得性肺炎中氟喹诺酮类药物使用的影响。
在研究期间(1997年4月1日至2003年3月31日),新斯科舍省9个地区卫生当局的37家医院中有31家使用了氟喹诺酮类药物。使用ATC/DDD方法汇总了1997/1998财年至2002/2003财年与这些药物使用相关的医院管理数据、医院特征和药品采购数据。对地区药房主任进行了调查,以获取有关地区和各医院抗生素政策的信息。计算了描述性统计数据,并进行了单变量回归和多水平分析。
在研究期间,氟喹诺酮类药物的总体平均使用量有所增加,从1997/1998财年的每年47.2 DDD/1000床日增加到2002/2003财年的每年163.8 DDD/1000床日(p<0.001)。多水平分析表明,旨在合理处方的使用政策并未影响氟喹诺酮类药物的使用。
本研究表明,药物采购、医院管理和诊断数据可以结合起来,以比较不同医院和地区卫生当局之间氟喹诺酮类药物的使用情况。使用政策对氟喹诺酮类药物的使用量、类型或给药途径影响不大。